Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals

Дата публикации: 02-07-2026 19:52:14

Lawmakers step into a dispute between Eli Lilly and hospitals about the 340b drug discount program.

Основное содержимое страницы с новостью.

By Ed Silverman

July 2, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Dozens of congressional lawmakers are urging the Trump administration to force Eli Lilly to reinstate mandated price breaks to hospitals that participate in a federal drug discount program but have refused to provide the company with claims data.

In a letter to Department of Health and Human Services Secretary Robert F. Kennedy Jr., the bipartisan group of lawmakers argued that Lilly is failing to comply with federal law by eliminating the price breaks. The drugmaker stopped offering discounts last month to reduce what it calls duplicate discounts paid to the hospitals.

At the time, Lilly targeted 50 larger hospital systems among approximately 1,000 hospitals that had not complied with a new policy that was announced this year. The company maintained that roughly 70% of the hospitals that participate in the discount program, or more than 2,300, had previously provided claims data.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1STAT+: Medicare takes another swing at 340B cuts to hospitals0502-07-2026
2STAT+: Cassidy proposes bill to rein in 340B drug discount program0525-06-2026
3STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more0502-07-2026
4STAT+: Embryo editing advances reignite ethical debates0526-06-2026
5STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more0510-07-2026
6Supreme Court rules in weedkiller cancer case0526-06-2026
7STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings0502-07-2026
8STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug0502-07-2026
9Депутаты подготовили законопроект против завышения цен в аптеках0005-02-2020
10Lawmakers discuss direct contracting as solution to lower healthcare costs0502-07-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.statnews.com.